Dimensional Fund Advisors LP Acquires 414,019 Shares of Cascadian Therapeutics Inc (CASC)

Dimensional Fund Advisors LP lifted its holdings in Cascadian Therapeutics Inc (NASDAQ:CASC) by 423.0% during the 3rd quarter, Holdings Channel reports. The firm owned 511,899 shares of the biopharmaceutical company’s stock after acquiring an additional 414,019 shares during the quarter. Dimensional Fund Advisors LP’s holdings in Cascadian Therapeutics were worth $2,094,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in CASC. New York State Common Retirement Fund acquired a new position in shares of Cascadian Therapeutics in the 2nd quarter worth approximately $136,000. Rhumbline Advisers acquired a new position in shares of Cascadian Therapeutics in the 2nd quarter worth approximately $143,000. Schwab Charles Investment Management Inc. acquired a new position in shares of Cascadian Therapeutics in the 2nd quarter worth approximately $225,000. California State Teachers Retirement System acquired a new position in shares of Cascadian Therapeutics in the 2nd quarter worth approximately $226,000. Finally, Teachers Advisors LLC acquired a new position in shares of Cascadian Therapeutics in the 2nd quarter worth approximately $252,000. 80.35% of the stock is currently owned by institutional investors.

Several equities analysts have recently issued reports on the stock. ValuEngine raised shares of Cascadian Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Wednesday, January 31st. Zacks Investment Research raised shares of Cascadian Therapeutics from a “hold” rating to a “buy” rating and set a $4.50 price objective on the stock in a research note on Monday, November 13th. BidaskClub raised shares of Cascadian Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, January 31st. Finally, Raymond James Financial cut shares of Cascadian Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Wednesday, January 31st. Three investment analysts have rated the stock with a sell rating, two have issued a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $5.63.

Cascadian Therapeutics Inc (NASDAQ:CASC) opened at $9.97 on Friday. Cascadian Therapeutics Inc has a 1 year low of $3.18 and a 1 year high of $10.21.

Cascadian Therapeutics (NASDAQ:CASC) last released its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.28) earnings per share for the quarter, topping the consensus estimate of ($0.29) by $0.01. During the same quarter in the previous year, the company earned ($0.09) earnings per share. sell-side analysts predict that Cascadian Therapeutics Inc will post -1.27 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Dimensional Fund Advisors LP Acquires 414,019 Shares of Cascadian Therapeutics Inc (CASC)” was originally posted by Community Financial News and is owned by of Community Financial News. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of United States & international trademark and copyright legislation. The original version of this article can be viewed at https://www.com-unik.info/2018/02/09/dimensional-fund-advisors-lp-acquires-414019-shares-of-cascadian-therapeutics-inc-casc.html.

About Cascadian Therapeutics

Cascadian Therapeutics, Inc, formerly Oncothyreon Inc, is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. The Company’s clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor (HER) 2 inhibitor.

Want to see what other hedge funds are holding CASC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cascadian Therapeutics Inc (NASDAQ:CASC).

Institutional Ownership by Quarter for Cascadian Therapeutics (NASDAQ:CASC)

Receive News & Ratings for Cascadian Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cascadian Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit